Topic: R&D spending

Dog at Vet

Nexvet doubles down on R&D spending as net loss widens

It's been a rough ride for Dublin-based Nexvet ever since the company offered its shares to the public in February at $10 a piece. By the time it announced its fiscal 2015 earnings results on Sept. 3, its shares had fallen to $4.27, as its two lead drugs to treat osteoarthritis in pets have produced mixed results in clinical trials. The numbers clearly show the company is still laboring to define the future of its late-stage pipeline.